-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
"Investment logic" and "fundamental" are what investors are most concerned about for listed companies.
Often in the earnings disclosure season, companies with bright earnings reports can rise by a wave, but this year's interim report disclosure season, the leading pharmaceutical stocks that once led the industry have received wave after wave of performance kills
Gloria British Hillhouse cuts rare limit
Gloria British Hillhouse cuts rare limitAmong the leading pharmaceutical companies that have suffered performance kills, Kailaiying (002821.
On the whole, this performance is as stable as ever, but because of careful comparison, the company's operating income and main business gross profit margin are not as good as market expectations, plus the investment indicator-Hillhouse Capital reduced its holdings in the second quarter Half of the shares are regarded as a major negative
As a result, Kailaiying was firmly pressed on the lower limit at the opening of the market on August 16.
Changchun Hi-tech, the storm continues to overjoy the performance, but the market is not enough to buy it
Changchun Hi-tech, the storm continues to overjoy the performance, but the market is not enough to buy itAfter rumors of centralized procurement, major shareholder reductions, growth hormone abuse and other topics have been widely discussed, the stock price of "Northeast Yaomao" Changchun High-tech (000661.
It seems to be to restore market confidence.
There is no doubt that this is a beautiful financial report.
It is worth mentioning that for the criticism that Xinhua News Agency’s name "Zenggao Needle" will cause endocrine disorders, slippage of the femoral head, scoliosis, etc.
According to an inquiry from Sina Pharmaceuticals, some parents also said that for the side effects of the appeal, they had already signed the relevant "Informed Consent" before giving their children growth hormone, and they had long known about these side effects
Therefore, whether Changchun Hi-tech will find it difficult to recover from the news of centralized procurement, growth hormone abuse, etc.
The picture comes from the Internet
Hengrui, Mindray, WuXi AppTec.
Hengrui, Mindray, WuXi AppTec.
During the constant decline and fall of Hengrui Medicine, its status as the No.
I thought the gap would widen, but in a blink of an eye, Mindray Medical and WuXi AppTec were also killed
From the beginning of June 2021 to the present, Mindray Medical has continued to fall.
In almost the same period, WuXi AppTec also fluctuated all the way down to only 129.
95 yuan/share as of today, which is 172.
49 yuan/share from the highest point, which has fallen by about 33%
.
On August 13, WuXi AppTec announced its semi-annual report.
The net profit in the first half of 2021 increased by 56% year-on-year.
The market did not respond to the rise
.
Up to now, Hengrui and Mindray's 2021 semi-annual report has not been disclosed
.
Finally, let’s review the highlights of the pharmaceutical stocks at the beginning of this year:
"Pharmaceutical stocks broke out! 13 have a market value of 100 billion yuan, Hengrui breaks 600 billion, Mindray is pressing ahead, WuXi AppTec exceeds 400 billion.
.
.
"
